Eris Lifesciences Ltd received a show cause notice from the Directorate General of GST Intelligence alleging non-payment of IGST on its acquisition of trademark rights for Zomelis from Novartis AG on November 27, 2019, with a potential IGST demand of approximately Rs. 16.84 crores, plus interest of 18% per annum since that date.